Fig 2. Abatacept enhances the levels of IL-35⁺IL-10⁺ and IL-35⁺ producing CD19⁺ cells in lung tissues and peripheral blood of OVA- sensitized mice.

(A) Percentage of CD19⁺ cells in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice, and in the normal control mice. (B-C) Percentage of IL-35⁺IL-10⁺ producing B cells and IL-35⁺ producing B cells in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. (D) Percentage of CD19⁺ cells in the PBMCs of abatacept IN, abatacept IP treated, or OVA challenged mice, and in the normal control mice. (E-F) Percentage of IL-35⁺IL-10⁺ producing B cells and IL-35⁺ producing B cells in the PBMCs of abatacept IN, abatacept IP treated, or OVA challenged mice. Lung tissues of 5 mice and PBMCs of 10 mice were used. Two-way unpaired t-test was used to calculate significance. * ***P < 0.001. Events were recorded and analysed by using BD FACSDiva version 8.0.